PVLA: Pieris Pharmaceuticals O‘sish sur’atini hisobga olgan kapitalizatsiyaning sof foydaga nisbati
Yuqori patent to'siqlari va FDA ning qat'iy nazorati raqobatchilar uchun sezilarli to'siqlarni yaratadi. P/E o'sish potentsiali ko'rsatkichi aktivning dinamikasini aks ettiradi, bunda joriy daraja 0.00 ni tashkil etadi. Pieris Pharmaceuticals (PVLA) ulkan sinov xarajatlariga qaramay, biznesni startaplardan himoya qiluvchi noyob protein portfelini saqlab qolmoqda. Kompaniya hozirda chuqur restrukturizatsiyadan o'tmoqda, vaqtincha tijorat daromadlarisiz qolgan va xarajatlarni cheklamoqda.
Pieris Pharmaceuticals (PVLA) kompaniyasi koʻrsatkichlari kesimi va tahlili
- aksiya narxi va baholash bo'yicha konsensus prognoz:
- bozor kapitallashuvi haqida ma'lumot:
- kompaniyaning balans qiymati tafsilotlari:
- emitentning kredit yuki va likvidlik ko'rsatkichlari:
Umumiy qarzning kapitalga nisbati Pieris Pharmaceuticals|PVLA - Uzoq muddatli qarzning o'z kapitaliga nisbati|Qisqa muddatli qarzning kapitalga nisbati ko'rsatkichi pieris.com|PVLA - Kompaniyaning jamlangan qarzlari|Balans qiymatiga qarzlar Pieris Pharmaceuticals Inc|PVLA - Kompaniyaning uzoq muddatli qarzi|Qisqa muddatli majburiyatlar Pieris Pharmaceuticals|Oraliq qoplama koeffitsiyenti pieris.com
- biznes foydasi va investitsiya koeffitsiyentlari ma'lumotlari:
PVLA - Sof foyda|Kutilayotgan sof foyda Pieris Pharmaceuticals|PVLA - Narxning foydaga nisbati|Kelajakdagi narx-foyda multiplikatori Pieris Corp|PVLA - PEG multiplikatori|Kompaniyaning to‘liq qiymatining amortizatsiyadan oldingi operatsion foydaga nisbati Pieris Pharmaceuticals Inc|PVLA - Foizlar, soliqlar va eskirish to'lanishidan oldingi foyda|So'nggi to'rtta chorak uchun bir aksiya uchun sof foyda Pieris Pharmaceuticals|PVLA - So'nggi 12 oy davomida bir aksiya uchun sof foyda|So'nggi 12 oy davomida bitta aksiya uchun foydaning yillik o'sishi pieris.com|PVLA - Joriy yilda bir aksiya uchun foyda o'sishi|Kelgusi yil uchun bir aksiya uchun sof foydaning o'zgarishi prognozi Pieris Pharmaceuticals
Kompaniyaning umumiy tahlili:PVLA - Pieris Pharma
Investorlar Pieris Pharmaceuticals (PVLA) moliyaviy hisobotlaridan biznesning bozor qiymati adolatli ekanligini baholash uchun fundamental mezonlarni qidirmoqdalar. O'sishga yo'naltirilgan ushbu P/E ko'rsatkichi narx-foyda nisbatini kompaniyaning kengayish sur'atlari bilan solishtiradi; birdan past qiymat aktivlar proprietary Anticalin platformasi va strategik B2B sherikliklar orqali uzoq muddatli qiymat yaratuvchi himoyalangan patent perimetri potensialiga nisbatan past baholanganligini anglatadi.
Pieris Pharmaceuticals raqobatchilari
ARGX (argenx N.V.) - O‘sish sur’atini hisobga olgan qoplash koeffitsiyenti|PEG multiplikatori BNTX (BioNTech Group)|O‘sish sur’atini hisobga olgan kapitalizatsiyaning sof foydaga nisbati Abivax (ABVX)|ADMA - Narxning foydaga va o‘sish sur’atiga nisbati|protagonist-inc.com (PTGX) - Narx-foyda va o‘sish multiplikatori|Immunovant (IMVT) - Narxning foydaga va o‘sish sur’atiga nisbati|Narx-foyda va o‘sish multiplikatori Kiniksa Pharmaceuticals, Ltd.|Narx-foyda va o‘sish multiplikatori GRFS|PEG multiplikatori Adaptive Biotechnologies Inc.|Narxning foydaga va o‘sish sur’atiga nisbati Celldex Therapeutics (CLDX)|auriniapharma.com - O‘sishni hisobga olgan narx-foyda koeffitsiyenti|PEG multiplikatori BCRX (BioCryst Pharmaceuticals)|Vera Therapeutics Inc (VERA) - O‘sish sur’atiga tuzatilgan narx-foyda|DNTH - Narxning foydaga va o‘sish sur’atiga nisbati|Kapitalizatsiyaning foyda va o‘sish sur’atiga nisbati PHVS|ABCL: PEG multiplikatori|TRML - O‘sish sur’atini hisobga olgan kapitalizatsiyaning sof foydaga nisbati|PGEN (Precigen) - PEG multiplikatori|O‘sish sur’atiga tuzatilgan narx-foyda Pharming Group NV PHAR|Narxning foydaga va o‘sish sur’atiga nisbati Nektar (NKTR)|UPB (Upstream Pharma) - O‘sish sur’atini hisobga olgan qoplash koeffitsiyenti|PEG multiplikatori ZBIO (Zenas Biopharma Inc)|O‘sish sur’atini hisobga olgan kapitalizatsiyaning sof foydaga nisbati immunome.com (IMNM)|GOSS - Narxning foydaga va o‘sish sur’atiga nisbati|O‘sish sur’atini hisobga olgan kapitalizatsiyaning sof foydaga nisbati KalVista Pharma KALV|SEPN (Septerna Corp) - Narx-foyda va o‘sish multiplikatori|Savara Pharma - O‘sish sur’atini hisobga olgan qoplash koeffitsiyenti|Narxning foydaga va o‘sish sur’atiga nisbati Rigel Pharmaceuticals|anaptysbio.com - Kapitalizatsiyaning foyda va o‘sish sur’atiga nisbati|PEG multiplikatori ATXS|ENGN (enGene Holdings Inc) - O‘sish sur’atini hisobga olgan qoplash koeffitsiyenti|PEG multiplikatori RAPT (RAPT Therapeutics, Inc.)|PEG multiplikatori Aerovate Therapeutics, Inc. JBIO|ACRS - Narxning foydaga va o‘sish sur’atiga nisbati|O‘sish sur’atini hisobga olgan qoplash koeffitsiyenti KYTX (kyvernatx.com)|Tiziana Life Sciences Ltd (TLSA) - Narxning foydaga va o‘sish sur’atiga nisbati|Narx-foyda va o‘sish multiplikatori Cabaletta Bio Inc.|VTYX (Ventyx Bio) - PEG multiplikatori|PEG multiplikatori Theratechnologies, Inc|PEG multiplikatori AVTX|Narx-foyda va o‘sish multiplikatori eledon.com ELDN|PEG multiplikatori AGEN (Agenus Inc.)|Climb Bio Inc. (CLYM) - O‘sish sur’atiga tuzatilgan narx-foyda|ZURA: Narx-foyda va o‘sish multiplikatori|ATYR - PEG multiplikatori|ADAG (adagene.com) - Narx-foyda va o‘sish multiplikatori|IMA: Kompaniya qiymatining foyda o‘sish sur’atiga nisbati|STTK (Shattuck Labs Inc) - PEG multiplikatori|Equillium Bio (EQ) - O‘sish sur’atini hisobga olgan kapitalizatsiyaning sof foydaga nisbati|PEG multiplikatori CNTB|Narx-foyda va o‘sish multiplikatori immunic-therapeutics.com IMUX|PEG multiplikatori ATRA (Atara Bio)|PEG multiplikatori InflaRx NV IFRX|XFOR - Narxning foydaga va o‘sish sur’atiga nisbati|ACET: Narxning foydaga va o‘sish sur’atiga nisbati|celularity.com (CELU) - Narxning foydaga va o‘sish sur’atiga nisbati|INMB - O‘sish sur’atini hisobga olgan kapitalizatsiyaning sof foydaga nisbati|Narxning foydaga va o‘sish sur’atiga nisbati Barinthus Biotherapeutics|kezarlifesciences.com - Kapitalizatsiyaning foyda va o‘sish sur’atiga nisbati|Narx-foyda va o‘sish multiplikatori SABS (SAB Biotherapeutics, Inc.)|Narxning foydaga va o‘sish sur’atiga nisbati AKTX (Akari Therapeutics PLC)|Narxning foydaga va o‘sish sur’atiga nisbati Enlivex Therapeutics Ltd. ENLV|Q32 Bio Inc - Narxning foydaga va o‘sish sur’atiga nisbati|GeoVax Labs, Inc. - PEG multiplikatori|EDSA - PEG multiplikatori|iBio (IBIO) - Narxning foydaga va o‘sish sur’atiga nisbati|Kapitalizatsiyaning foyda va o‘sish sur’atiga nisbati CARM (Carisma Therapeutics Inc.)|XTLB (XTL Biopharmaceuticals, Ltd.) - PEG multiplikatori|BOLT: O‘sish sur’atini hisobga olgan qoplash koeffitsiyenti|PEG multiplikatori HCWB|PEG multiplikatori aptevotherapeutics.com (APVO)|Narxning foydaga va o‘sish sur’atiga nisbati AIM ImmunoTech AIM|O‘sish sur’atini hisobga olgan qoplash koeffitsiyenti ADTX|GRI - Narxning foydaga va o‘sish sur’atiga nisbati|XORTX Corp (XRTX) - Narx-foyda va o‘sish multiplikatori|HIND: PEG multiplikatori|revbiosciences.com (REVB) - PEG multiplikatori|Narx-foyda va o‘sish multiplikatori INDP|SCNI: O‘sish sur’atini hisobga olgan qoplash koeffitsiyenti|PEG multiplikatori CALI|O‘sish sur’atini hisobga olgan kapitalizatsiyaning sof foydaga nisbati affimed.com|Narxning foydaga va o‘sish sur’atiga nisbati Allakos ALLK|HOOK - Narx-foyda va o‘sish multiplikatori|IGMS - Narxning foydaga va o‘sish sur’atiga nisbati|iTeos Therapeutics Inc (ITOS) - Narx-foyda va o‘sish multiplikatori|OCEA (Ocean Bio) - Narx-foyda va o‘sish multiplikatori|TC BioPharm Ltd (TCBP) - PEG multiplikatori|Narxning foydaga va o‘sish sur’atiga nisbati Third Harmonic Bio
